×
About 11,066 results

ALLMedicine™ Thrombocytopenia Center

Research & Reviews  5,273 results

Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a ran...
https://doi.org/10.1182/bloodadvances.2020002790
Blood Advances; Tang Y, Chen J et. al.

Mar 1st, 2021 - Refractory prolonged isolated thrombocytopenia (RPIT) is an intractable complication after allogeneic hematopoietic cell transplantation (HCT), which often leads to poor prognosis. A clinical study was designed to validate the efficacy and safety ...

Clinical variability in multifocal lymphangioendotheliomatosis with thrombocytopenia: a...
https://doi.org/10.1080/08880018.2020.1871135
Pediatric Hematology and Oncology; Manor J, Patel K et. al.

Mar 1st, 2021 - Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) is a recently recognized disorder characterized by vascular lesions marked by distinct endothelial proliferation. Lesions affect multiple tissues, and MLT can be associated with re...

Platelet-Activating Immune Complexes Identified in Critically Ill COVID-19 Patients Sus...
https://doi.org/10.1111/jth.15283
Journal of Thrombosis and Haemostasis : JTH; Nazy I, Jevtic SD et. al.

Feb 27th, 2021 - Thrombocytopenia and thrombosis are prominent in coronavirus disease 2019 (COVID-19), particularly amongst critically ill patients; however, the mechanism is unclear. Such critically ill COVID-19 patients may be suspected of heparin-induced thromb...

Increased Expression of IL-17A and IL-17F Is Correlated With RUNX1 and RORγT in Pediatr...
https://doi.org/10.1097/MPH.0000000000002108
Journal of Pediatric Hematology/oncology; Elnaenaey WA, Omar OM et. al.

Feb 26th, 2021 - Immune thrombocytopenia (ITP) is characterized by dysregulated cellular immunity. Interleukin 17 (IL-17) and its secreting cells (Th17) are involved in the pathogenesis of ITP. Retinoic acid receptor-related orphan receptor γt (RORγt) is the chief...

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin recept...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905908
Journal of Hematology & Oncology; Mei H, Liu X et. al.

Feb 26th, 2021 - Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and saf...

see more →

Guidelines  17 results

American Society of Hematology 2019 guidelines for immune thrombocytopenia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963252
Blood Advances; Neunert C, Terrell DR et. al.

Dec 3rd, 2019 - Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients. These evidence-based guidelines of t...

Dova Pharmaceuticals Announces Fda Approval Of Supplemental New Drug Application For Doptelet® (Avatrombopag) For Treatment Of Chronic Immune Thrombocytopenia (ITP)
http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-approval-supplemental-new

Jun 26th, 2019 - Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the U.S. Food and Drug Administration (FDA) ap...

American Society of Hematology 2018 guidelines for management of venous thromboembolism...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258919
Blood Advances; Cuker A, Arepally GM et. al.

Nov 29th, 2018 - Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism. These evidence-based ...

American Society of Hematology 2018 guidelines for management of venous thromboembolism: hep...
http://www.bloodadvances.org/content/2/22/3360
Cuker, A.

Nov 26th, 2018 - Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism.

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy an...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278058
Chest Linkins LA, Dans AL et. al.

Feb 14th, 2012 - Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction that can lead to devastating thromboembolic complications, including pulmonary embolism, ischemic limb necrosis necessitating limb amputation, acute myocardial in...

see more →

Drugs  121 results see all →

Clinicaltrials.gov  5,473 results

Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a ran...
https://doi.org/10.1182/bloodadvances.2020002790
Blood Advances; Tang Y, Chen J et. al.

Mar 1st, 2021 - Refractory prolonged isolated thrombocytopenia (RPIT) is an intractable complication after allogeneic hematopoietic cell transplantation (HCT), which often leads to poor prognosis. A clinical study was designed to validate the efficacy and safety ...

Clinical variability in multifocal lymphangioendotheliomatosis with thrombocytopenia: a...
https://doi.org/10.1080/08880018.2020.1871135
Pediatric Hematology and Oncology; Manor J, Patel K et. al.

Mar 1st, 2021 - Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) is a recently recognized disorder characterized by vascular lesions marked by distinct endothelial proliferation. Lesions affect multiple tissues, and MLT can be associated with re...

Platelet-Activating Immune Complexes Identified in Critically Ill COVID-19 Patients Sus...
https://doi.org/10.1111/jth.15283
Journal of Thrombosis and Haemostasis : JTH; Nazy I, Jevtic SD et. al.

Feb 27th, 2021 - Thrombocytopenia and thrombosis are prominent in coronavirus disease 2019 (COVID-19), particularly amongst critically ill patients; however, the mechanism is unclear. Such critically ill COVID-19 patients may be suspected of heparin-induced thromb...

Increased Expression of IL-17A and IL-17F Is Correlated With RUNX1 and RORγT in Pediatr...
https://doi.org/10.1097/MPH.0000000000002108
Journal of Pediatric Hematology/oncology; Elnaenaey WA, Omar OM et. al.

Feb 26th, 2021 - Immune thrombocytopenia (ITP) is characterized by dysregulated cellular immunity. Interleukin 17 (IL-17) and its secreting cells (Th17) are involved in the pathogenesis of ITP. Retinoic acid receptor-related orphan receptor γt (RORγt) is the chief...

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin recept...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905908
Journal of Hematology & Oncology; Mei H, Liu X et. al.

Feb 26th, 2021 - Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and saf...

see more →

News  161 results

Mycophenolate Shows Promise in Immune Thrombocytopenia
https://www.medscape.com/viewarticle/942584

Dec 13th, 2020 - A drug currently used to prevent rejection in patients who receive solid organ transplants could have a use in the treatment of a completely different patient population ― those with immune thrombocytopenia (ITP). The drug is mycophenolate mofetil...

Mycophenolate a Potential First-line Therapy for ITP
https://www.medscape.com/viewarticle/942374

Dec 9th, 2020 - Treatment-naïve immune thrombocytopenia (ITP) patients could more than halve their risk of treatment failure with mycophenolate alongside a course of corticosteroids compared with corticosteroids alone, conclude UK researchers in the first randomi...

Falling Splenectomy Rates in ITP Raise Questions Over Role
https://www.medscape.com/viewarticle/929773

May 10th, 2020 - Patients with immune thrombocytopenia (ITP) are undergoing fewer and fewer splenectomies later and later in the disease course, which is resulting in lower gains from the procedure, say UK researchers, who question its ongoing role. The research w...

BET inhibitor exhibits activity in myelofibrosis
https://www.mdedge.com/hematology-oncology/article/215490/cythemias/bet-inhibitor-exhibits-activity-myelofibrosis/page/0/1?channel=50517

Jan 14th, 2020 - Safety “CPI-0610 monotherapy or as an add-on to [ruxolitinib] was generally well tolerated,” Dr. Mascarenhas said.

Age, sex, and other factors linked to risk of intracranial hemorrhage in ITP
https://www.mdedge.com/hematology-oncology/article/214454/bleeding-disorders/age-sex-and-other-factors-linked-risk?channel=39313
Jennifer Smith

Dec 17th, 2019 - ORLANDO – A large, retrospective study suggests several factors are associated with an increased risk of intracranial hemorrhage in patients with immune thrombocytopenia. Jennifer Smith/MDedge News Mayank Sharma Data on more than 300,000 immune th.

see more →

Patient Education  21 results see all →